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Abstract
Chronic wounds represent an important challenge for wound care and are universally 
colonized by bacteria. These bacteria can form biofilm as a survival mechanism that 
confers the ability to resist environmental stressors and antimicrobials due to a variety 
of reasons, including low metabolic activity. Additionally, the exopolymeric substance 
(EPS) contained in biofilm acts as a mechanical barrier to immune system cells, leading 
to collateral damage in the surrounding tissue as well as chronic inflammation, which 
eventually will delay healing of the wound. This chapter will discuss current knowledge 
on biofilm formation, its presence in acute and chronic wounds, how biofilm affects anti-
biotic resistance and tolerance, as well as the wound healing process. We will also discuss 
proposed methods to eliminate biofilm and improve wound healing despite its presence, 
including basic science and clinical studies regarding these matters.
Keywords: biofilm, chronic wounds, delayed healing, exopolymeric substance, slime, 
extracellular matrix
1. Introduction
Intact skin provides a protective barrier to bacterial invasion. Any wound comprises a break 
in this epidermal barrier, allowing microbial invasion into deeper layers.
Along with hypoxia/poor perfusion, ischemia-reperfusion injury, and inadequate offloading 
or compression therapy, microbial infection is one of the most significant causes of delay in 
healing [1–3].
Over the last few years, bacterial biofilms in general and their role in chronic wounds have 
been the subject of intense research. Biofilms have been reported to be present in 60% [4] to 
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80% [5] of chronic wounds, and a recent meta-analysis confirms their presence in 78.2% of 
chronic wounds [2]. Therefore, biofilms have been categorized as an important factor in most 
chronic non-healing skin wounds [6].
Non-healing or poorly healing wounds affect close to 25 million people in the US [7], more than 
7% of its population, while reports from the UK [8] predict that 1–2% of the population in devel-
oped countries will experience a chronic wound in their lifetime. Posnett et al. [9] reports the 
financial burden to the healthcare system of caring for chronic wounds in the UK, totaling US$ 
3.4–4.6 billion a year, close to 3% of the healthcare budget. The US, a larger and more complex 
system, observed $35.3 billion in spending of Medicare funds on wound care alone in 2014, of 
which 16.7 billion was spent on infections and 9.4 billion on chronic ulcers [9] (Figure 1).
The implications of a biofilm-covered wound are not limited to delayed healing and finan-
cial burden. Biofilms pose a risk for persistent wound infections, especially when medical 
hardware is inserted into the body [11]. Biofilms can also develop into an overt infection, 
contribute to antimicrobial resistance, and increase the risk for adverse or tissue toxic effects 
caused by topical agents [12].
2. Background
Wound healing can be deranged by multiple causes, including local hypoxia or poor perfu-
sion, repetitive ischemia-reperfusion injury, inadequate offloading or compressive therapy, 
and bacterial infection. Bacterial infection, playing a great role among these causes, has been 
Figure 1. Representative scanning electron microscopy of wounds on mice dorsal skin. (A) Inoculated wound with S. 
aureus showed aggregates encased in EPS matrix. (B) Non-inoculated wound without EPS (image from Nguyen et al. 
[10], with permission).
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associated with both acute and chronic wounds via different rates and mechanisms. An 
infection with a more predominantly planktonic phenotype is more aggressive, with rapidly 
dividing cells invading host tissues and stimulating a strong inflammatory response typical of 
an acute infection. Several microorganisms can adopt a different, sessile phenotype, called a 
biofilm, that allows them to attach to biotic or abiotic surfaces, form aggregates, and regulate 
the production of an extracellular polymeric substance (EPS), contributing to their ability to 
survive [13, 14] (Table 1).
This aggregate or cluster, once called “slime,” constitutes the biofilm, a complex tertiary 
structure of sessile communities of one or more species of bacteria embedded within a 
matrix of EPS. The EPS is composed mainly by water, polysaccharides, DNA and other 
substances secreted by the embedded bacteria, but also by substances scavenged from the 
host. It is important to appreciate that all the building blocks of a wound biofilm are ulti-
mately derived from the wound bed and skin. Cell lysis and subsequent local decomposi-
tion of the EPS matrix is advantageous for the biofilm population, creating new pores and 
channels that improve nutrient access, and the intracellular level of the second messenger 
cyclic di-GMP are involved in regulating biofilm formation and the production of matrix 
components [15].
For many years, biofilm has been known to exist on dental plaque and industrial water pro-
cessing and even considered the predominant state of bacteria within the human body [16]. 
Later on, its presence was reported on endocardium, urinary tract mucosa, nasal and sinus 
epithelium and pulmonary tissue, and more recently biofilms have been found in healed sur-
gical wounds, sutures, implants and IV catheters which can be contaminated at time of inser-
tion or as a result of hematologic seeding from a colonized tissue. The relationship between 
biofilm and host will depend on the location and the bacterial composition of the biofilm; for 
instance, in the gastrointestinal mucosa, biofilm has a commensal behavior, while in wounds 
or respiratory tract mucosa, a pathogenic behavior. This difference is thought to be due to the 
host’s capacity to coexist or eradicate biofilm [6, 12, 17, 18].
Planktonic vs. biofilm phenotype
Trait Planktonic Biofilm
Virulence Acute, aggressive course Chronic disease
Host inflammatory response High, sudden Mild, persistent
Risk for antibiotic resistance Moderate High
Spread Disseminating Sessile
Extracellular polymetric substance (EPS) No Yes
Metabolic activity High Low
Species count Monospecies, polyspecies Polyspecies
Table 1. Planktonic and biofilm phenotypes comparison in regards to various bacterial traits and behaviors.
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Figure 2. The extracellular polymeric substances matrix at different dimensions. (a) A model of a bacterial biofilm attached 
to a solid surface. (b) The major matrix components—polysaccharides, proteins and DNA—in a non-homogeneous 
pattern. (c) Physicochemical interactions and the entanglement of biopolymers that give stability to the EPS matrix. (d) A 
molecular modelling simulation of the interaction between alginate (right) and lipase (left) of P. aeruginosa (image from 
Flemming and Wingender [15], with permission).
3. Composition of biofilm
Several functions have been attributed to biofilm: genetic material reservoir, nutrient source, 
matrix stabilization, adhesion, and bacterial communication. Most of these functions will 
depend on the particular substances present in the biofilm, which depend exclusively on the 
species and even the strain of the bacteria. For instance, P. aeruginosa produces a biofilm with 
a higher density EPS, with a well-defined matrix interspersed within clusters of bacterial cells 
and has the particularity to be predominant over other species in a polybacterial microbiome. 
In general, the interaction of these substances and how the bacteria inside the biofilm manage 
to utilize these substances will affect the morphology of the biofilm with common effects: 
immobilizing biofilm cells and allowing the existence of a very diverse habitat favoring biodi-
versity, where every member can contribute with their own EPS [15] (Figure 2).
3.1. Polysaccharides
Polysaccharides comprise a major fraction of the EPS matrix and are responsible for the 
biofilm’s mechanical properties. Interestingly, it seems to be mainly the exopolysaccharides 
in multivalent inorganic ions with EPS can greatly influence the mechanical properties of 
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biofilms. For instance, presence of Ca2+ in biofilm formed by mucoid strains of P. aeruginosa 
experienced an enhancement in their mechanical stability. In S. epidermidis, poly-N-acetylglu-
cosamine (PNAG) makes a considerable contribution to biofilm integrity [15].
As seen in P. aeruginosa and S. epidermidis, polysaccharide compositions are very diverse, even 
between strains of a single species. P. aeruginosa, for instance, produces at least three distinct 
exopolysaccharides that have a direct effect on its biofilm architecture: alginate, Pel and Psl. 
Mucoid strains of P. aeruginosa contain alginate, an exopolysaccharide for biofilm formation 
that, although non-essential, has a notable effect on biofilm architecture. Alginate takes part 
at the beginning of biofilm formation and is responsible for the mechanical stability of mature 
biofilms. Alginate from this strain has a particular clinical relevance, being comprised of 
uronic acids, in that it can be used as an EPS marker, since this type of acid is not found inside 
the bacterial cells. In non-mucoid strains, Pel and Psl participate in the first stages of biofilm 
formation, while Psl alone is involved in adherence to surfaces [15].
3.2. Proteins
Biofilms also contain a diversity of enzymes, lending a complex organization and capability 
of adaptation. Enzymes will break down biopolymers into low molecular mass products, 
degrade the structural EPS to promote detachment, act as virulence factors, and even degrade 
EPS components during starvation. Cell surface-associated proteins and extracellular carbo-
hydrate-binding proteins (lectins) are also a key component in the biofilm, involved in the 
formation and stabilization of the matrix network [15].
Among these proteins we can find the glucan-binding proteins present in dental plaque 
caused by S. mutans, the galactose-specific lectin lecA and fucose-specific lectin lecb of P. aeru-
ginosa, which have been associated with biofilm formation. Biofilm associated surface protein 
(bap) from S. aureus and the bap-like proteins, which promote biofilm formation in several 
species while also playing a role in bacterial infectious processes. Biofilms also contain amy-
loids, involved in adhesion to inanimate surfaces and host cells and invasion of host cells; 
additionally, they can function as cytotoxins for bacterial and plant cells [15].
3.3. Extracellular DNA
eDNA is an integral part of the matrix and biofilm mode of life. B. cereus uses DNA as an 
adhesion molecule, and in P. aeruginosa, eDNA serves as an intercellular connector, with 
DNase inhibiting biofilm formation specifically in P. aeruginosa. In S. aureus, eDNA serves the 
same structural role of PNAG in S. epidermidis eDNA, although seen initially as residual mate-
rial from lysed cells, is also actively excreted. Although primarily occurring in waste-water 
biofilms, biofilms from various origins have been found to contain eDNA of varying levels 
and importance, even between closely related species. For example, eDNA plays a critical 
structural role in the biofilm matrix of S. aureus but only serves as a minor component of 
S. epidermidis biofilms. eDNA is localized differently between biofilms; in P. aeruginosa, for 
example, forms a grid-like structure. Additionally, eDNA has antimicrobial activity, having 
the ability to chelate cations that stabilize lipopolysaccharide and the bacterial outer mem-
brane, provoking cell lysis [15].
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3.4 Water and biosurfactants
Water is by far the largest component of the matrix, and water management is so critical 
that bacteria actively respond to desiccation by producing EPS. Molecular composition of the 
water component is critical as well, and the EPS matrix acts as a molecular sieve, sequestering 
cations, anions, nonpolar compounds and particles from the water phase. By comparison, 
biosurfactants have antibacterial and antifungal properties and are important for bacterial 
attachment and detachment from oil droplets. Rhamnolipids, which can act as surfactants, 
have been found in the EPS matrix of P. aeruginosa [15] (Table 2).
4. Pathophysiology
4.1. Biofilm development
Biofilms utilize a variety of mechanisms in order to establish themselves. When exposed 
to adverse conditions, planktonic bacteria facilitate survival by forming biofilms. This 
occurs through “phase variation” and “adaptive mutation,” genetic alterations that include 
point mutations, recombination, and transpositions, with the goal of producing individuals 
more capable of producing biofilms. V. cholera, S. typhi, and E. coli all exhibit stress-induced 
genetic alteration by adaptive mechanisms that produce a biofilm-capable phenotype, pro-
ducing distinct, wrinkled individuals. V. cholera produces a more chlorine-resistant subtype 
called rugose, while S. typhi and E. coli change to an “rdar” phenotype, or red, dry, and 
rough [19].
4.2. Biofilms and chronic disease
By establishing biofilms, bacterial species not only increase their antibiotic resistance 1000-fold, 
they produce optimal conditions for chronic infections. By sacrificing aggressive movement 
throughout the body for confinement within a protective extracellular matrix, bacterial species 
effectively hide antigens, reduce the effectiveness of antibiotics, and blunt the immune response, 
promoting chronic disease: endocarditis, chronic kidney stones, and CF infections [19, 20]. 
EPS composition
Component Function(s)
Polysaccharides Mechanical strength, adherence
Proteins Mechanical strength, adherence, detachment, virulence
eDNA Mechanical strength, adherence, antimicrobial, genetic transfer
Water Source of ions and compounds in solution
Biosurfactants Adherence, detachment
Table 2. Composition of biofilm exopolymeric substance (EPS) and associated functions.
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Biofilms play a significant role in the development of chronic cutaneous wounds, with up 
to 80% of chronic wounds having been found to contain a biofilm compared to 6% of acute 
wounds [2, 4, 5, 21].
Biofilms cause chronic infections through mechanisms that are either innate or interact closely 
with the host immune system: genetic changes, surface and excreted molecular messengers, 
physical barriers, and escape behaviors. Although the bacteria may not disseminate throughout 
the body, pathogenicity is retained and arguably increased, as bacterial concentration within 
the biofilm increases and individuals tend to leave the biofilm, either through purposeful dis-
solution of EPS or through stresses on the biofilm itself by the fluid encasing the biofilm [19].
When bacteria cluster in a biofilm, movement of advantageous genetic traits, such as antibiotic 
resistance, throughout the constituents of the biofilm is expedited through transformation, 
horizontal gene transfer, or phage infection, making each individual bacterium even more 
virulent when it leaves the biofilm. P. aeruginosa biofilms, for example, exhibit a high concen-
tration of DNA within their EPS. This also promotes significant genetic variability within a 
biofilm, increasing the chances that one of the many individuals will survive an environmen-
tal insult [19]. This includes antibiotics, leading to concern that excessive and inappropriate 
antibiotic use against biofilms expedites the development of antibiotic resistant strains [12].
4.3. Wound healing inhibition
Biofilms involve a complex relationship between bacteria virulence factors, survival mecha-
nisms, and the host immune response [22]. Different species all exhibit particular biofilm 
characteristics that inhibit wound healing. EPS by itself represents a physical barrier against 
inflammatory cell phagocytosis, and has the potential to inhibit the complement cascade and 
antibiotic penetration into the wound [23]. Acellular extract from S. aureus biofilms inhib-
its the movement of keratinocytes and promotes apoptosis, leading to impaired cutaneous 
wound healing. This extract did not differ in pH or calcium levels; its effect on keratinocytes 
was due to direct cytotoxic substances secreted from or present on S. aureus bacterium: alpha-
toxin and cell surface-expressed fibronectin-binding proteins [21].
P. aeruginosa biofilms similarly inhibit neutrophil movement but may spare their capacity for 
oxidative burst, and exhibit a capacity for ejecting individual bacterium from the biofilm [24]. 
Another potential mechanism for P. aeruginosa biofilm resistance to neutrophils is the rapid 
necrosis induced by the production of rhamnolipids [23]. Additionally, significant delay in wound 
healing, re-epithelization and collagen deposition have been reported without significant differ-
ence in PMN infiltration or granulation tissue [6]. The ultimate result is neutrophil aggregation 
near the biofilm, with oxidative burst products accumulating and causing neutrophil death, while 
individuals within the biofilm leave to create new colonies away from the initial site [24, 25].
Biofilms in general promote a host inflammatory response that poorly penetrates the bio-
film itself, causing surrounding cell damage instead [18]. Host inflammatory signal expres-
sion also characterizes the biofilm infection; in general, those with impaired host immune 
responses, such as those with diabetes or arterial insufficiency, tend to have more significant 
wounds [22].
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S. aureus biofilms promote a distinct profile of IL-1β and TNF-α expression indicative of a mild 
but chronic inflammatory response [17]. While mild inflammation is helpful towards eradicat-
ing the infection by attracting an immune response and increasing collagen synthesis and granu-
lation tissue formation, persistently high amounts of IL-1β and TNF-α decrease growth factors 
and increase metalloproteases, delaying resolution of the infection and wound healing [20].
P. aeruginosa in particular exhibits the highest virulence compared to S. aureus and K. pneu-
moniae due to this reason; P. aeruginosa biofilms exhibit the lowest bacterial counts but cause 
the highest elevation in IL-1β and TNF-α compared to the other two strains [23]. MRSA bio-
films modulate the immune response by stimulating macrophages towards an M2 instead of 
M1 response, inhibiting inflammation and promoting fibrosis [26]. Chronic diseases caused 
by biofilms, in essence, are due to a complex equilibrium between bacterial defenses and the 
host immune response (Figure 3).
5. Antibiotic resistance mechanisms
Biofilms are notoriously resistant to antibiotics, making them frustrating to treat, particularly 
in implanted devices, where usually the most viable solution is replacing the device entirely [27, 28]. 
Figure 3. Biofilm pathophysiology. Common pathways followed by bacteria to chronic infection and wound healing 
impairment.
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Most literature cites the exopolymeric substance (EPS), serving as a physical barrier, as a 
cause of antibiotic resistance, and this is seen in some species; P. aeruginosa EPS contains 
negatively-charged alginate that easily slows the diffusion of positively-charged aminogly-
cosides [22, 23, 27].
However, some specific pairs of antibiotics and species do exhibit unrestricted diffusion: cip-
rofloxacin and ampicillin through K. pneumoniae, rifampin through S. epidermidis, ciprofloxa-
cin through P. aeruginosa, and tetracycline through E. coli, illustrating that although the EPS 
does contribute, there are many more factors, related to or independent from the EPS, that 
contribute in sum to resistance [27].
While the EPS does indeed slow diffusion of antibiotic, eventually enough antibiotic will 
accumulate and kill the offending pathogen; this result has been observed in P. aeruginosa 
with tobramycin, despite the alginate produced. An important role, then, of the EPS is not 
blocking the antibiotic, but slowing its effect and allowing the bacteria within the biofilm to 
prepare. Antibiotics, for example, can stimulate the production of additional EPS in S. epider-
midis, E. coli, and P. aeruginosa [27].
More specifically, a variety of antibiotics stimulated polysaccharide intracellular adhesion 
production in S. epidermidis, and beta-lactam antibiotics upregulated cps gene expression in E. 
coli, promoting the production of colonic acid; both are critical for biofilm formation in their 
respective species. As for P. aeruginosa, imipenem stimulated alginate production and the arr 
gene was found to influence biofilm resistance to aminoglycosides [27].
Within the biofilm, constituent bacteria construct a hypoxic and nutrient-deprived micro-
environment that slows bacterial division and, as a result, blunts the effect of antibiotics. 
Factors for chronic disease and antibiotic resistance in biofilms
Factor Function Examples
EPS Block host detection of bacterial 
antigens, inflammatory response, and 
effect of antibiotics
Alginate in mucoid P. aeruginosa
Molecular messengers/host 
immune modulation
Establishes chronic infection and 
inhibits host inflammatory response 
and wound healing
S. aureus biofilms impair keratinocytes; P. 
aeruginosa biofilms impair neutrophils
Genetic changes Genetic diversity, exchange of virulence 
factors and antibiotic resistance genes
Horizontal gene transfer, eDNA, phage 
infection, transformation
Escape behaviors Promote establishment of new colonies 
away from site under antimicrobial or 
immune system attack
S. viridans seeding from dental plaque to 
endocardium
Persister phenotype Increased resistance to antibiotics E. coli persister genes glpD, glpABC, plsD
Stress response genes Increased resistance to antibiotics E. coli rpoS gene
Environmental alterations Reduction of bacterial division and 
susceptibility to antibiotics targeting 
division
Low oxygen, nutritional state 
microenvironment within the biofilm
Table 3. Mechanisms by which biofilms lead to chronic disease, with associated functions and examples.
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For example, E. coli increases cydAB and b2997-hybABC genes expression. Along with this 
micro-environment, bacteria establish a stationary-phase state and express stress response 
genes; E. coli increases rpoS expression, while P. aeruginosa increases groES, dnaK, catalase, 
katA, and katB [27].
Biofilm bacteria also increase the population of slow-growing “persisters,” particularly hardy 
individual bacterium that can resist antibiotics. In E. coli, glpD, glpABC, plsD, are critically 
involved in persister development, as well as chromosomal toxin/antitoxin genes relE and 
hipBA. Finally, there are also specific biofilm-only products, such as ndvB in P. aeruginosa, that 
specifically target certain antibiotics, in this case tobramycin [27] (Table 3).
6. Diagnosis
Bacterium often do not present purely in a planktonic or biofilm state; infections often con-
tain a mixture of both. Basic criteria of the present of a biofilm are proposed by Parsek and 
Singh [19] and include the following: (1) bacteria are attached to a particular surface, (2) when 
examined, bacteria are organized into groups surrounded by EPS, (3) the infection is isolated 
to a particular area, and (4) the infection is difficult to treat with antibiotics despite significant 
eradication when in planktonic form.
Current diagnosis of wound infections is based on the bacterial side of the infection, rather 
than the host side; culturable CFUs is the most basic diagnostic tool but limits the diagnosis 
to only culturable bacteria [29]. Additionally, as biofilms are an observed mode of growth for 
bacteria in living hosts, it is difficult to sample a suspected host and have the bacteria establish 
the same biofilm on culture [19].
Furthermore, a significant amount of biofilms contain multiple species, an average of 5.4 
and a maximum of 106 [18, 25]. PCR surpasses this limitation and allows clinicians to 
detect unculturable species, but the severity of the infection cannot be assessed in a multi-
species infection [29]. There has also been success in determining biofilm formation by P. 
aeruginosa in CF patients by measuring the ratio between two quorum sensing messengers 
[19]. Autoinducers indicating virulence factor expression is another proposed diagnostic 
measurement [18].
Newer proposed tests measure the host side of the infection beyond clinical assessment, 
where the appearance of inflammatory signs can be unreliable and change over time. New 
upcoming methods of diagnosing and assessing the severity of chronic wounds revolve 
around measuring host inflammatory markers [29].
However, tests must be designed around each individual species’ unique course and pro-
file of inflammatory markers, as well as the unique relationship between the inflammatory 
marker levels and virulence; for example, P. aeruginosa exhibits the lowest bacterial counts but 
the highest IL-1β and TNF-α response, as compared to S. aureus and K. pneumoniae [22, 23].
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7. Management of biofilm
Even though there is not a standard debridement type, frequent sharp and mechanical debride-
ment have been suggested as the standard treatment for biofilm infection. Nevertheless, 
up to 30% [30] of biofilm infected wounds continued unresolved after these, and therefore 
other options are being considered, such as biological, enzymatic and autolytic [12, 30–33]. 
Mechanical debridement involves the application of wound dressings that expedite wound 
healing and resolve the biofilm infection [12]. For example, silver-based dressing is effective 
against P. aeruginosa biofilms [16]. Additionally, antimicrobial coatings, on inserted devices, 
for example, can hinder biofilm formation [27]. Sharp debridement, by contrast, involves 
scraping away at the wound with a sharp instrument to remove necrotic tissue [12]. Beyond 
debridement, many other treatment modalities for biofilms are being explored, including 
molecular solutions, energy-based interventions, and new topical medications.
Given the complex interactions between biofilm bacterium, the physical extracellular matrix, 
secreted signals and toxins, and the host immune response, there are understandably many 
molecular solutions for disrupting the biofilm and promoting resolution of chronic wounds. 
Among these, we have the following:
• Furanone, a substance structurally similar to a class of quorum sensing signal produced by 
the marine alga Delisea pulchra, has been successfully used to treat V. harvey, B. subtilis, and P. 
aeruginosa biofilms. Furanone acts by disrupting quorum sensing using this similarity [27].
• Patulin, a molecule found in Penicillium extracts has the ability to disrupt quorum-sensing, 
and also was proven to be effective against P. aeruginosa biofilm pulmonary infection in a 
mouse model, acting synergistically with tobramycin [27].
• Farnesol, produced by C. albicans is effective against S. aureus biofilms by compromising 
its membrane integrity, additionally, it increases the effect of Gentamycin on MRSA and 
methicillin sensitive S. aureus [27].
• Ursolic acid, a natural plant extract, also disrupts P. aeruginosa, V. harvey, and E. coli biofilms 
via a mechanism that is not completely dilucidated, involves several bacterial metabolic 
activities except quorum-sensing [27].
• Staphylococcal accessory regulator (sarA) has been identified as a key regulator for biofilm 
formation, and therefore is, in effect, a potential therapeutic target. sarA mutant strains of 
S. aureus and S. epidermidis experienced limited biofilm formation and increased suscepti-
bility to daptomycin [28].
• For MRSA in particular, due to its particular trait of promoting a fibrotic M2 response, 
rather than a strongly inflammatory M1 response, inserting M1 macrophages or stimu-
lating such a response using EP67 can prevent MRSA biofilms entirely and also resolves 
MRSA biofilms better than antibiotics or administration of neutrophils. EP67 is a CD88 
agonist that converts an M2 response by increasing the amount of inflammatory cytokines 
produced and increases the potency of macrophage movement into the biofilm [26].
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• Ribonucleic acid III inhibiting peptide (RIP) is a promising new intervention for biofilms, 
as it inhibits the quorum sensing necessary for biofilms to form [34]. RIP treatment accel-
erates wound healing in S. aureus and S. epidermidis biofilms to equal that of uninfected 
wounds. RIP also exhibits increased effect when combined with antibiotics in the treatment 
of S. epidermidis infections in devices [27].
• d-amino acids is a specific mix containing d-tyrosine, d-leucine, d-tryptophan and d-methi-
onine that form a factor that was first found to prevent biofilm formation in B. subtilis, and 
later on tested on P. aeruginosa and S. aureus. In S. aureus, another combination (d-phenylal-
anine, d-proline, d-tyrosine) was found to be more effective and, more importantly, that its 
action is targeted to the growth stage of biofilm formation [23, 35, 36].
However, treatment cannot only consist of quorum sensing inhibitors or interventions that 
specifically target the biofilm, as bacteria can still survive and grow in planktonic form; dap-
tomycin is the antibiotic of choice most effective against biofilm-forming bacteria [28].
Energy-based therapeutic options, such as ultrasound, are another viable option for treating 
biofilms; for P. aeruginosa biofilms, daily or every other day low frequency ultrasound is effec-
tive in reducing inflammation and improving wound healing [16, 37]. Additional research has 
also investigated the application of different topical medications on biofilm resolution and 
wound healing; for example, wound healing from S. aureus biofilms benefits from exposed 
desiccation or the application of honey or molasses on the wound site compared to saline, 
exhibiting greater granulation tissue and decreased inflammation, primarily due to the action 
of air or osmotic agents in drying the wound [38].
8. Conclusions
Contrasting with free-floating, acutely infectious planktonic forms of bacteria, a biofilm is an 
aggregated colony of bacteria, usually of multiple species, that produces a protective EPS and 
establishes a microenvironment within that is conductive to survival and ultimately leads 
to chronic infection in the form of kidney stones, pulmonary infections, endocarditis, and 
cutaneous non-healing wounds.
When exposed to environmental stressors, bacterial undergo genetic changes that pro-
mote biofilm formation. Biofilms are made up of multiple elements—polysaccharides, 
proteins, extracellular DNA, and water/biosurfactants—all which have unique structural 
and functional traits that establishes the biofilm and its properties. Biofilms are a primary 
cause of chronic cutaneous wounds, due to the secretion of signals that inhibit a proper 
host immune response. While each species’ biofilm is different in its particular properties, 
make-up, and response to antibiotics, biofilms are, in general, notoriously difficult to treat 
using antibiotics due to the EPS blocking the diffusion of antibiotics and allowing the pro-
duction of a microenvironment conductive to gene transfer, metabolic slowing, selection 
for hardier individuals, and the development of escape behaviors that create new biofilms 
elsewhere in the body.
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Biofilms are clinically diagnosed with four basic criteria—attached, organized, local, and anti-
biotic resistant. Assessment with older culture methods has been proven inefficient. Modern 
methods such as PCR and detection of molecular inflammatory markers and secreted bacterial 
products are more useful methods of diagnosis. While the standard treatment is frequent and 
aggressive debridement, there are multiple modalities for the treatment of biofilms—biologic, 
enzymatic, autolytic, and mechanical—with newer molecular treatments in combination with 
traditional antibiotic therapy showing promising results.
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